Target therapy for hepatocellular carcinoma: Is sorafenib for everybody?

Journal of Clinical Gastroenterology

Volumn 43, Issue 5, 2009, Pages 389-390

  Daniele, Bruno ^a   Di Maio, Massimo ^b  

^a G RUMMO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADVANCED CANCER; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; DESQUAMATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG INDICATION; DRUG TOLERABILITY; DRY SKIN; EARLY DIAGNOSIS; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; PRIORITY JOURNAL; PROGNOSIS; RASH; SKIN TOXICITY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; PYRIDINES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67651115584     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31819eb9a6     Document Type: Editorial

References (14)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4:424-432.
3. El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134:1752-1763.
4. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48:S20-S37.
5. Daniele B, Annunziata M, Barletta E, et al. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatol Res. 2007;37(suppl 2):S206-S209.
6. Huang M, Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett. 1999; 135:97-105.
7. Kato A, Miyazaki M, Ambiru S, et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol. 2001;78:110-115.
8. Kuo MT, Zhao JY, Teeter LD, et al. Activation of multidrug resistance (Pglycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ. 1992;3:531-540.
9. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
10. Worns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroentrol. 2009;43:489-495.
11. Miller AA, Daryl JM, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009. Available at http://jco. ascopubs.org/cgi/doi/10.1200/JCO.2008.20. 0931.
12. Abou-Alfa GK, Amadori D, Santoro A, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol. 2008;26(May 20 suppl):abstract 4518.
13. Di Maio M, Daniele B, Gallo C, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:1557.
14. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-4300. (Pubitemid 46630787)